To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

December 14, 2023

NEW SonALAsense Clinical Trials for rGBM & DIPG Patients

sonalescence banner
brain drawing

The goal of SonALAsense is to turn cancer patients into cancer survivors. SonALAsense was founded to create hope in the face of despair with Sonodynamic Therapy (SDT), a non-invasive way to treat and eradicate deadly cancers like High-Grade Gliomas that typically require debilitating brain surgery that often leads to tumor recurrence.

SonALAsense’s SDT is a non-invasive targeted combination of SONALA-001 (Intravenous Aminolevulinic Acid) and MR-guided focused ultrasound. 

SonALAsense is currently recruiting for two trials. The first is SDT-201 Phase 1/2 Clinical Trial for Pediatric Patients with Diffuse Intrinsic Pontine Glioma (DIPG). The second is SDT-202 Phase 1/2 Clinical Trial for Adults with Recurrent Glioblastoma (rGBM).

Contact Shreya Prakash

brain scan illustration

Sponsor logos


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram